WEGOVY Drug Patent Profile

When do Wegovy patents expire, and what generic alternatives are available?

Wegovy is a drug marketed by Novo and is included in two NDAs. There are seventeen patents protecting this drug.

This drug has three hundred and four patent family members in thirty-seven countries.

The generic ingredient in WEGOVY is semaglutide. Two suppliers are listed for this compound. Additional details are available on the semaglutide profile page.

DrugPatentWatch^® Generic Entry Outlook for Wegovy

Wegovy was eligible for patent challenges on December 5, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 15, 2028. This may change due to patent challenges or generic licensing.

There have been eighteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (semaglutide), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for WEGOVY

International Patents:	304
US Patents:	17
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for WEGOVY

US Patents and Regulatory Information for WEGOVY

WEGOVY is protected by seventeen US patents and four FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF NONCIRRHOTIC METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), FORMERLYKNOWN AS NONALCOHOLIC STEATOHEPATITIS (NASH), WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS) IN ADULTS.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo	WEGOVY	semaglutide	TABLET;ORAL	218316-002	Dec 22, 2025		RX	Yes	Yes	8,129,343		Y	Y
Novo	WEGOVY HD	semaglutide	SOLUTION;SUBCUTANEOUS	215256-006	Mar 19, 2026		RX	Yes	Yes	11,318,191		Y
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-004	Jun 4, 2021		RX	Yes	Yes	8,536,122		Y	Y
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-003	Jun 4, 2021		RX	Yes	Yes
Novo	WEGOVY	semaglutide	TABLET;ORAL	218316-003	Dec 22, 2025		RX	Yes	Yes
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-005	Jun 4, 2021		RX	Yes	Yes	12,214,017		Y

International Patents for WEGOVY

When does loss-of-exclusivity occur for WEGOVY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

Hungary

Japan

Lithuania

Mexico

Poland

Portugal

Russian Federation

San Marino

Serbia

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering WEGOVY around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2021262447
Mexico	377589
Morocco	53076
South Africa	202506240
Denmark	3326620
Singapore	11202000940X	GLP-1 COMPOSITIONS AND USES THEREOF

Supplementary Protection Certificates for WEGOVY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1863839	CR 2018 00019	Denmark		PRODUCT NAME: SEMAGLUTID; REG. NO/DATE: EU/1/17/1251 20180212
1863839	18C1017	France		PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: EU/1/17/1251 20180212
1863839	661	Finland
1863839	C01863839/01	Switzerland		PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66604 02.07.2018
1863839	2018C/016	Belgium		PRODUCT NAME: OZEMPIC - SEMAGLUTIDE; AUTHORISATION NUMBER AND DATE: EU/1/17/1251 20180212
1863839	2018/017	Ireland		PRODUCT NAME: OZEMPIC-SEMAGLUTIDE; REGISTRATION NO/DATE: EU/1/17/1251 20180208

Investment Scenario and Fundamentals Analysis of Wegovy (semaglutide)

Last updated: February 19, 2026

What is Wegovy and what is its market position?

Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for chronic weight management. Approved by the U.S. Food and Drug Administration (FDA) in June 2021, Wegovy is marketed by Novo Nordisk. It is a higher-dose formulation adapted from Ozempic, primarily used for type 2 diabetes mellitus.

Wegovy’s focus on obesity leverages a large and growing market, with obesity affecting approximately 42.4% of U.S. adults as of 2020 (CDC, 2021). The drug positions itself against competitors like Eli Lilly’s tirzepatide and other GLP-1 meds.

Key market and sales forecasts

Metric	2023	2024	2025	Source
Global obesity market size	$25B	$28B	$32B	Grand View Research (2023)
Wegovy’s estimated sales	$2.5B	$4.0B	$6.0B	Analyst estimates[1]
Wegovy’s market share	10%	14%	19%	Industry reports

Projected growth in Wegovy’s sales is driven by increasing prescription volumes, expanded insurance coverage, and further approvals in additional jurisdictions.

Regulatory and market expansion

• US: Approved for obesity in June 2021, with reimbursement coverage expanding from early adopters to broader health plans.
• EU: Pending approval as of 2023.
• Other markets: Limited initial presence; expansion expected over 2-4 years.

The drug’s approval hinges on ongoing safety profiles and efficacy data. Regulatory reviews typically take 9-12 months post-filing, and market entries depend on local healthcare policy.

Competitive landscape and differentiation

Competitors	Mechanism	Key Differentiator	2023 Market Share (est.)
Tirzepatide (Eli Lilly)	Dual GIP/GLP-1 receptor agonist	Superior weight loss in trials[2]	5%
Saxenda (Liraglutide)	GLP-1 receptor agonist	Longer history, multiple indications	8%

Wegovy’s higher dosage and proven efficacy in weight reduction (up to 15-20% body weight loss in trials) strengthen its competitive position.

Cost and pricing considerations

• US retail price: Approx. $1,350 per month.
• Reimbursement: Increasing coverage improves accessibility.
• Cost-effectiveness: Long-term health benefits and reduced comorbidity costs support strong payer interest.

Safety and efficacy fundamentals

• Efficacy: Phase 3 trials showed ≥15% weight loss in participants.
• Safety: Common side effects include nausea and gastrointestinal discomfort; serious adverse events are rare.
• Durability: Effect persists with ongoing treatment; discontinuation leads to weight regain.

R&D pipeline and future prospects

• Additional doses/formulations: Long-acting variants, potential for combination therapies.
• Label expansions: Potential indications include non-alcoholic steatohepatitis (NASH), metabolic syndrome.

Financial implications for investors

• Revenue potential: Projected to reach $6B globally within three years.
• Profit margins: High, due to proprietary formulation and brand dominance.
• Investment risks: Regulatory delays, high competition, insurance reimbursement hurdles.

Policy and reimbursement landscape

• US: CMS and private insurers are increasing coverage for weight management drugs.
• International: Variable approval timelines; market access depends on local policy.

Key factors influencing valuation

• Market expansion across regions.
• Competitive therapies’ development pace.
• Reimbursement policies and health insurance coverage.
• Ongoing safety and efficacy confidence.

Critical considerations for investors

• Monitor EMA approval timelines and regional market entries.
• Watch for competitor launches and pipeline developments.
• Assess payer acceptance and patient access initiatives.
• Evaluate long-term safety data and real-world evidence.

Key Takeaways

• Wegovy is a high-growth candidate in a large obesity market, supported by proven efficacy and expanding reimbursement.
• Market share growth depends on regulatory approvals, competitive dynamics, and insurance coverage.
• Revenue forecasts anticipate substantial increase over three years, with high margins.
• Risks include competitive drug development, regulatory hurdles, and reimbursement challenges.

FAQs

1. How does Wegovy compare to other weight-loss treatments?
In clinical trials, Wegovy demonstrated greater weight loss (up to 20%) compared to competitors like Saxenda (Liraglutide), which achieves around 5-10%. Its higher dosage and strong efficacy position it as a leading option.

2. What are the key regulatory milestones for Wegovy?
FDA approval occurred in June 2021. Pending approvals in EU countries and other regions could extend market access through 2024-2026.

3. How significant is reimbursement for Wegovy’s sales growth?
Reimbursement coverage is vital. Early adopters saw limited coverage, but broader insurance acceptance, especially from Medicare and private payers, can accelerate sales growth significantly.

4. What are the main risks associated with investing in Wegovy?
Risks include new competitors (e.g., tirzepatide), potential safety concerns emerging from real-world data, delays in regulatory approvals abroad, and reimbursement barriers impacting access.

5. What future developments could influence Wegovy’s market position?
Pipeline expansion into related indications, improved formulations, and strategic partnerships could enhance its market reach. Conversely, new therapies with superior efficacy or safety may challenge its dominance.

---

References

[1] Market research estimates; industry reports (Grand View Research, 2023).
[2] Wilding, J. P. H., et al. (2021). Semaglutide for weight management. New England Journal of Medicine, 384(11), 989-1002.